ALNY Strangle Strategy
ALNY (Alnylam Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics.
ALNY (Alnylam Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $38.92B, a trailing P/E of 67.11, a beta of 0.30 versus the broader market, a 52-week range of 266.18-495.55, average daily share volume of 1.1M, a public-listing history dating back to 2004, approximately 2K full-time employees. These structural characteristics shape how ALNY stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.30 indicates ALNY has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 67.11 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a strangle on ALNY?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ALNY snapshot
As of May 15, 2026, spot at $288.91, ATM IV 40.00%, IV rank 22.84%, expected move 11.47%. The strangle on ALNY below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ALNY specifically: ALNY IV at 40.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a ALNY strangle, with a market-implied 1-standard-deviation move of approximately 11.47% (roughly $33.13 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ALNY expiries trade a higher absolute premium for lower per-day decay. Position sizing on ALNY should anchor to the underlying notional of $288.91 per share and to the trader's directional view on ALNY stock.
ALNY strangle setup
The ALNY strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ALNY near $288.91, the first option leg uses a $300.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ALNY chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ALNY shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $300.00 | $10.20 |
| Buy 1 | Put | $270.00 | $6.35 |
ALNY strangle risk and reward
- Net Premium / Debit
- -$1,655.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$1,655.00
- Breakeven(s)
- $253.45, $316.55
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ALNY strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ALNY. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$25,344.00 |
| $63.89 | -77.9% | +$18,956.15 |
| $127.77 | -55.8% | +$12,568.30 |
| $191.65 | -33.7% | +$6,180.45 |
| $255.52 | -11.6% | -$207.40 |
| $319.40 | +10.6% | +$285.25 |
| $383.28 | +32.7% | +$6,673.10 |
| $447.16 | +54.8% | +$13,060.94 |
| $511.04 | +76.9% | +$19,448.79 |
| $574.92 | +99.0% | +$25,836.64 |
When traders use strangle on ALNY
Strangles on ALNY are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ALNY chain.
ALNY thesis for this strangle
The market-implied 1-standard-deviation range for ALNY extends from approximately $255.78 on the downside to $322.04 on the upside. A ALNY long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ALNY IV rank near 22.84% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ALNY at 40.00%. As a Healthcare name, ALNY options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ALNY-specific events.
ALNY strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ALNY positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ALNY alongside the broader basket even when ALNY-specific fundamentals are unchanged. Always rebuild the position from current ALNY chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ALNY?
- A strangle on ALNY is the strangle strategy applied to ALNY (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ALNY stock trading near $288.91, the strikes shown on this page are snapped to the nearest listed ALNY chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ALNY strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ALNY strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 40.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,655.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ALNY strangle?
- The breakeven for the ALNY strangle priced on this page is roughly $253.45 and $316.55 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ALNY market-implied 1-standard-deviation expected move is approximately 11.47%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ALNY?
- Strangles on ALNY are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ALNY chain.
- How does current ALNY implied volatility affect this strangle?
- ALNY ATM IV is at 40.00% with IV rank near 22.84%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.